1 肿瘤基因检测

目前,随着越来越多肿瘤靶向药物和免疫药物的获批上市,甚至纳入医保,基因检测已经逐渐成为肿瘤治疗的常规手段。基于这些靶向药物的多样性,临床检测需求已经从单一基因推进到了多基因平行检测——NGS检测则可以一次性检测几十甚至几百个基因,筛查全部用药的可能性,并弥补传统方法不能对免疫标志物TMB、MSI检出的不足。

查看更多
2 燃石LAVA精准诊疗数据社区

随着医学领域的快速发展和人们对肿瘤发病分子机制认识的不断深入,肿瘤治疗逐渐从前基因组的细胞毒性药物治疗时代过渡到后 基因组的靶向治疗新时代,并不断朝着非单一分子标记物的免疫治疗时代努力探索。随着二代测序技术(NGS)在癌症诊疗过程中发挥 越来越重要的作用,尤其是免疫检查点抑制剂要求检测包含几百个基因的大Panel,临床医生也会面临随之而来的各种困境和挑战。

查看更多
3 燃石精准临床试验

肿瘤药物研发已经进入精准时代,分子肿瘤学和基因组学的进步对于靶向抗肿瘤药物的研发提出了新的挑战也制造了新的机遇。燃石医学“精准研究”项目服务于药企合作伙伴以提供更优化的试验设计以及帮助招募临床试验要求的具有特定基因变异的患者从而加快临床试验进度。

查看更多

燃石医学推出Magnis BR,革新NGS检测自动化全流程

发布日期:2019-11-18

联合安捷伦共同打造的黑科技,让NGS检测走进更多医院

“INGS-燃精准,应如石”再次点燃2019 CSCO,见证中国NGS进行时

发布日期:2019-10-10

2019年9月19日,第22届临床肿瘤学大会暨2019年CSCO学术年会将在厦门隆重之际,燃石医学在厦门国际会议中心海峡厅召开“INGS——燃精准,应如石”主题卫星会

学术合作

CTONG共建NGS实验室的首家合作伙伴

2016年8月,由中国胸部肿瘤研究协作组(Chinese Thoracic Oncology Group,CTONG)和燃石医学联合创建的二代基因测序(NGS)临床研究实验室在广州国际生物岛正式落成。该实验室将主要用于开展非营利性临床研究。占地约3000平方米的联合实验室包括19间独立实验室和办公区域,覆盖样本前处理、核酸提取、文库构建及测序,以及数据分析和报告生成四大核心环节的完整NGS检测流程,并采用国际一流的测序设备及国际标准的管理体系。中国临床肿瘤学会(CSCO)理事长吴一龙教授和燃石医学CEO汉雨生先生为联合实验室揭幕。

检测平台

占全球测序市场份额80%的IIIumina在中国的临床肿瘤战略合作伙伴,与IIIumina启动Miseq dx测序仪联合临床实验

2015年8月24日,燃石医学与美国illumina公司(NASDAQ:ILMN)在中国广州和美国圣迭戈正式宣布双方达成战略合作,就共同开发肿瘤个体化医疗基因检测平台签订协议。双方将合作开发专注于中国市场的、操作简便的肿瘤分子诊断试剂盒。作为合作的一部分,燃石医学将提供核酸提取、文库构建以及数据分析软件,同时,illumina将提供二代测序仪器和相关试剂。 美国Illumina公司是全球领先的新一代高通量测序仪供应商,也是大规模分析遗传变异和功能的生命科学工具及完整系统的领先开发商、制造商和营销商。这些系统实现了几年前甚至无法想象的研究,让人们距离个性化医疗的实现更近一步。

分子诊断解决方案

燃石医学将在中国开发基于Agilent SureSelect 靶向序列捕获系统的肿瘤基因检测,为中国肿瘤患者提供更多高品质的基于二代基因测序的分子诊断解决方案

2016 年 9 月 29 日,燃石医学与诊断与基因组学的全球领导者安捷伦科技公司(Agilent Technologies)宣布签订协议,根据协议,燃石医学将在中国开发基于Agilent SureSelect 靶向序列捕获系统的肿瘤基因检测,为中国肿瘤患者提供更多高品质的基于二代基因测序的分子诊断解决方案,包括肿瘤无创检测,复发监控,早期诊断和遗传易感性筛查等。

学术合作

搭建分享、讨论真实世界精准诊疗病例的平台,共同探索未知,推进精准诊疗实践。

“斐燃成章肿瘤精准案例巡展”由燃石医学自2017年2月发起,旨在搭建分享、讨论真实世界精准诊疗病例的平台,共同探索未知,推进精准诊疗实践。2017年,“斐燃成章”系列活动取得圆满成功,集合全国14个省市的40余家顶尖医院,分享60余个真实世界案例,参与的医学专业人士超过1500人次。 2018年,燃石医学携手CSCO Young、吴阶平医学基金会,进一步升级项目规模、形式和范围,从肺癌扩展至多个癌种,从个案分享扩展至同类案例队列,激发科研灵感,启发对同类案例更具普适性的临床建议。由吴一龙教授领衔、数十位专家组成的导师组,将对这些案例的完整性、典型性、启发性等多个维度进行评选。最终选拔出的全国优秀案例将获得“吴阶平-燃石医学青年医师种子基金”的鼓励。

学术合作

CSCO CAGC肺癌研究指定检测合作伙伴


CSCO(中国临床肿瘤学会)CAGC( 中国肿瘤驱动基因分析联盟)肺癌研究指定检测合作伙伴

分子诊断解决方案

凯杰(QIAGEN)中国在液体活检领域战略合作伙伴,保证燃石ctDNA样本制备技术和产品质量的可靠

2018年6月5日,燃石医学与凯杰(QIAGEN)中国达成合作协议,双方将在循环肿瘤DNA(ctDNA)液体活检领域展开全方位战略合作。燃石一直不断追求更高水平的质量标准,为医生和患者提供值得信赖的检测结果。QIAGEN 的ctDNA样本制备技术和产品质量可靠,纯化效率高,能帮助我们提高检测样本的核酸提取质量,从而使得检测结果更加准确。相信通过两家公司的强强联手,能为中国广大医生和患者带来高品质的基于二代基因测序的肿瘤分子诊断解决方案。

精准用药

阿斯利康肺癌NGS检测唯一战略伙伴,代表NGS方法学参与ASTRIS研究,参与L-moca奥拉帕利中国四期临床研究(HRD)

2016年,燃石医学与阿斯利康中国达成战略合作,燃石医学成为阿斯利康肺癌NGS检测战略伙伴。 2017年初,燃石医学携手中国妇女发展基金会与阿斯利康中国,推出中国卵巢癌领域首个NGS慈善公益项目—— “检爱•遇见未知的自己”BRCA卵巢癌慈善关爱项目。

1 Tumor Genetic Testing

At present, with more and more tumor targeted drugs and immune drugs approved for marketing and even included in medical insurance, genetic testing has gradually become a routine means of cancer treatment. Based on the diversity of these targeted drugs, clinical testing needs have evolved from a single gene to a multi-gene parallel test—NGS testing...

More
2 Burning Rock LAVA precision diagnosis & treatment data community

As medicine is booming and people go deeper in understanding the molecular mechanism for cancers, cancer treatment has evolved step by step from pregenome-based cytotoxic drug therapy to genome-based targeted therapy with constant efforts of probing into immunotherapy targeting multiple molecular markers. As the Next-Generation Sequencing (NGS) tec...

More
3 Burning Rock Precision Clinical Test

Research and development of cancer drug has embarked on a precision era. In this era, the progress in molecular oncology and genomics indicates a new challenge and opportunity in research and development of targeted anti-cancer drugs. Burning Rock “precision research” program therein takes aim at speeding up clinical tests by optimizing test design...

More

Burning Rock Dx Launches Magnis BR to Innovate Total Process Automation for NGS Testing

Var Date:2019-11-18

Exclusively supported by Agilent, this futuristic technology brings NGS testing to more hospitals

Burning Rock announces the completion of the Series C financing of RMB 850 million and strives to build an international leading tumor precision medicine brand

Var Date:2019-08-23

On February 14, 2019, Burning Rock held the signing ceremony and announced the closing of the Series C financing totaling RMB 850 million.

Academic Cooperation

CTONG's First Partner for Founding NGS Lab

In August 2016, Co-founded by Chinese Thoracic Oncology Group (CTONG) and Burning Rock Dx, the Next Generation Sequencing (NGS) Clinical Research Lab was duly inaugurated at Guangzhou International Bio Island. This lab is intended for non-profit clinical studies. The 3,000m2 lab comprises 19 independent labs and an office area, covers an intact NGS test process from sample library preparation, nucleic acid extraction, library building & sequencing to data analysis & report generating inclusive, adopts world-class sequencing equipment and complies with international standard management systems. Professor Wu Yilong, President Elect of Chinese Society of Clinical Oncology (CSCO), and Mr. Han Yusheng, CEO of Burning Rock Dx, unveiled a plaque to mark the inauguration of the lab.

Detection Platform

Burning Rock and America illumina Co. (NASDDAQ: ILMN) declared a strategic cooperation in Guangzhou and San Diego officially and signed an agreement on jointly developing a tumor individualistic medical gene detection.

On August 24, 2015, Burning Rock and America illumina Co. (NASDDAQ: ILMN) declared a strategic cooperation in Guangzhou and San Diego officially and signed an agreement on jointly developing a tumor individualistic medical gene detection. Both sides will cooperate to develop a tumor molecular diagnosis kit geared to Chinese market and easy to operate. As part of their cooperation, Burning Rock will provide nucleic acid extraction, construction of gene bank and data analysis software, while illumina will provide NGS instrument and related reagents. America illumina Co. is a globally leading supplier of new generation of high-flux sequencing instrument, and a leading developer, manufacturer and marketer of life science kit and complete system used to analyze hereditary mutations and functions on a large scale. These systems have realized researches which we could not imagine years ago and made us nearer to the fulfillment of individualistic medicine.

Molecular Diagnostics Solutions

Burning Rock Dx is planning to develop genetic cancer testing based on the Agilent SureSelect targeting sequence capture system in China to provide more high-quality NGS-based molecular diagnostics solutions for Chinese cancer patients

On September 29, 2016, Burning Rock Dx announced the conclusion of an agreement with a global diagnostics and genomics leader Agilent Technologies. As agreed, Burning Rock Dx is planned to develop genetic cancer testing based on the Agilent SureSelect targeting sequence capture system in China to provide more high-quality NGS-based molecular diagnostics solutions for Chinese cancer patients, including noninvasive cancer testing, recurrence monitoring, early diagnosis and genetic susceptibility screening among others.

Academic Cooperation

For building a platform for sharing and discussing precision diagnosis and treatment cases in real world, probing into the unknown and promoting precision diagnosis and treatment practice.

Initiated by Burning Rock Dx in February 2017, “FeiRanChengZhang Anti-cancer Precision Medicine Case Roadshow” was aimed at setting up a platform for sharing and discussion precision diagnosis and treatment cases in real world, probing into the unknown and promoting precision diagnosis and treatment practice. In 2017, the “FeiRanChengZhang” roadshow ended up with success. The roadshow involved 1,500+ medical professionals from 40+ top hospitals in 14 provinces and municipalities nationwide, where 60+ real world cases were shared. In 2018, Burning Rock Dx partnered with CSCO Young and Wu Jieping Medical Foundation to escalate the roadshow project in size, form and range. By expanding from lung cancer to a variety of cancers and from case sharing to similar case arraying, the project was redesigned to inspire inspiration in scientific research and more universal clinical advice to cases of the like. For that end, a panel of dozens of specialists led by Professor Wu Yilong will evaluate cases from a variety of dimensions including integrity, typicality, inspiration, etc. Finalized national outstanding cases will be granted with an incentive from “Wu Jieping-Burning Rock Dx Young Physician Seed Fund”.

Academic Cooperation

Designated testing partner to CSCO and CAGC in lung cancer research

Molecular Diagnostics Solutions

Burning Rock’s reassuring strategic partner in liquid biopsy - QIAGEN China with ctDNA sample preparation technology and high product quality

On June 5, 2018, Burning Rock Dx agreed with QIAGEN China to establish a strategic partnership in liquid biopsy for circulating tumor DNA (ctDNA) in all respects. Burning Rock keeps demanding on quality to offer testing results that can be trusted by doctors and patients. QIAGEN, with its ctDNA sample preparation technology and high product quality and purification efficiency can help Burning Rock improve quality of nucleic acid extracted from samples to produce more accurate testing results. It is believed that the two firms together can introduce high-quality NGS-based anti-cancer molecular diagnostics solutions to doctors and patients in China.

Precision Medicine

AstraZeneca's sole strategic NGS lung cancer testing partner involved in ASTRIS research and L-moca Olaparib stage-IV clinical research (HRD) in China

In 2016, Burning Rock Dx turned into AstraZeneca's lung cancer NGS testing partner by concluding a strategic partnership with AstraZeneca China. Earlier in 2017, Burning Rock Dx co-launched China's first non-profit NGS project targeting ovarian cancer-- ”Love Me, Test Me” public-welfare BRCA testing project for ovarian cancer patients.